Novo Nordisk CSO: Hemophilia Treatment ‘Segmenting’ Much Like In Diabetes
Executive Summary
Novo Nodisk's CSO says FDA approval of extended half-life Factor VIII Esperoct treatment for people with hemophilia A will give more choice to those patients and "effectively completes" the Danish group's hitherto R&D efforts based on clotting factor deficiencies.
You may also be interested in...
Novo Nordisk’s Concizumab Could Be First In New Class For Hemophilia
Phase III data for the drug showed strong efficacy among hemophilia A and B patients with inhibitors. The drug’s approval would help drive continued segmentation of the hemophilia market.
Novo Nordisk Halts Phase III Concizumab Hemophilia Trials After Three Thrombotic Events
No new patients will be enrolled, and trial participants will stop treatment with the tissue factor pathway inhibitor antibody, a class with four prior suspended hemophilia programs.
Keeping Track: US FDA Approves Esperoct, Tightens Chantix Label, Starts Review Of Alder’s CGRP Candidate
The latest drug development news and highlights from our US FDA Performance Tracker.